However, unique outcomes are also possible given the different cell contexts, the tumor type, and the fact that FGFR3 mutations are associated with an early stage and less aggressive form of cancer in the bladder, while in MM, FGFR3 mutations are more associated with cancer progression (Reviewed in [2], [4]). Here, FGFR3 is linked to neoplasm.